{"id":683690,"date":"2010-03-05T09:27:39","date_gmt":"2010-03-05T14:27:39","guid":{"rendered":""},"modified":"2026-10-04T11:13:16","modified_gmt":"2026-10-04T15:13:16","slug":"three-hcv-drug-candidates-proceed-to-phase-ii","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/683690","title":{"rendered":"Three HCV Drug Candidates Proceed to Phase II"},"content":{"rendered":"<p>Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing.<\/p>\n<p>Abbott, Enanta moving Hepatitis C drug development<\/p>\n<p>March 2, 2010<\/p>\n<p>NEW YORK<\/p>\n<p>Abbott Laboratories and partner Enanta Pharmaceuticals on Tuesday said they will move potential hepatitis C treatments into midstage development.<\/p>\n<p>The companies said they will evaluate three potential hepatitis C drugs in Phase 2 clinical trials. <\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.businessweek.com\/ap\/financialnews\/D9E6J6M81.htm\">http:\/\/www.businessweek.com\/ap\/financialnews\/D9E6J6M81.htm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing. Abbott, Enanta moving Hepatitis C drug development March 2, 2010 NEW YORK Abbott Laboratories and partner Enanta Pharmaceuticals on Tuesday said they will move potential hepatitis C treatments into midstage development. The companies said they will evaluate three potential hepatitis C drugs [&hellip;]<\/p>\n","protected":false},"author":288,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-683690","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-2RRg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/683690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/288"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=683690"}],"version-history":[{"count":1,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/683690\/revisions"}],"predecessor-version":[{"id":784799,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/683690\/revisions\/784799"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=683690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=683690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=683690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}